Hepatitis C Drug Costs More Than 1K a Pill

The recently approved drug to treat Hepatitis C comes with a hefty price tag.

Foster City, Calif.-based Gilead Sciences's Sovaldi received approval in December from the U.S. Food and Drug Administration.

The typical 12-week drug regimen costs $84,000, but some patients require the drug for a longer period of time, and guidelines suggest taking the drug along with others, adding to the overall care costs, according to a Kaiser Health News report.

J. Mario Molina, president and CEO of Molina Healthcare, a Medicaid managed care company, said in the report Medicaid programs like his will be hard hit by the financial burden of the drug.

"[Sovaldi is] far superior to anything we've had to treat hepatitis C. The problem is it's extraordinarily expensive," Mr. Molina said in the report.

Sovaldi has a success rate of more than 90 percent, and Gilead says its effectiveness warrants the high price, according to the report.

More Articles on Pharmaceuticals:

Pharmaceutical Companies Spending Less on Promotional Drug Speakers
FDA Approves Myalept to Treat Lipodystrophy Complications

Safety of Indian-Produced Drugs Being Questioned

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars